Clark G M, McGuire W L
Breast Cancer Res Treat. 1983;3(2):157-63. doi: 10.1007/BF01803558.
Estrogen receptor protein is known to be an important prognostic factor for patients with breast cancer. The presence of estrogen receptor correlates with response to endocrine therapy in patients with metastatic disease and is associated with prolonged disease-free and overall survival in patients with primary disease. But the correlation between estrogen receptor positivity and endocrine dependence is not perfect. Approximately 40% of estrogen receptor positive tumors fail to regress with endocrine therapy. It has been hypothesized that another protein, progesterone receptor, may be a more effective marker of endocrine responsiveness since progesterone receptor is the end product of estrogen action. We have examined the relationship between progesterone receptor and response of advanced breast cancer tumors to hormonal manipulations. Promising retrospective results indicate the need for new, prospective clinical trials to further define the prognostic value of progesterone receptor for these tumors. We have also analyzed the disease-free intervals of patients with primary disease and found that progesterone receptor was more important than estrogen receptor for predicting time to recurrence. We suggest that both estrogen receptor and progesterone receptor be routinely measured in all breast cancer tumors, and that the results of these assays will help the physician individualize therapy for breast cancer patients.
雌激素受体蛋白是已知的乳腺癌患者重要预后因素。雌激素受体的存在与转移性疾病患者对内分泌治疗的反应相关，并且与原发性疾病患者延长的无病生存期和总生存期相关。但是雌激素受体阳性与内分泌依赖性之间的相关性并不完美。大约40%的雌激素受体阳性肿瘤不会因内分泌治疗而消退。据推测，另一种蛋白，即孕激素受体，可能是内分泌反应性更有效的标志物，因为孕激素受体是雌激素作用的终产物。我们研究了孕激素受体与晚期乳腺癌肿瘤对激素操纵反应之间的关系。有前景的回顾性结果表明需要开展新的前瞻性临床试验，以进一步明确孕激素受体对这些肿瘤的预后价值。我们还分析了原发性疾病患者的无病间期，发现孕激素受体在预测复发时间方面比雌激素受体更重要。我们建议在所有乳腺癌肿瘤中常规检测雌激素受体和孕激素受体，并且这些检测结果将有助于医生为乳腺癌患者制定个体化治疗方案。
